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Objective: Previous population-based studies provided conflicting results regarding the 
association of total serum insulin-like growth factor I (IGF-I) and mortality. The aim of the 
present study was to assess the relation of IGF-I levels with all-cause mortality in a 
prospective study.  
Design: DETECT (Diabetes Cardiovascular Risk-Evaluation: Targets and Essential Data for 
Commitment of Treatment) is a large, multistage, and nationally representative study of 
primary care patients in Germany. The study population included 2463 men and 3603 women. 
Death rates were recorded by the respective primary care physician. Serum total IGF-I levels 
were determined by chemiluminescence immunoassays and categorized into three groups 
(low, moderate, and high) according to the sex- and age-specific 10th and 90th percentiles.  
Results: Adjusted analyses revealed that men with low [hazard ratio (HR) 1.70 (95% 
confidence interval [CI] 1.05–2.73), p=0.03] and high [HR 1.76 (95% CI 1.09–2.85), p=0.02] 
IGF-I levels had higher risk of all-cause mortality compared to men with moderate IGF-I 
levels. The specificity of low IGF-I and high IGF-I levels increased with lower and higher 
cut-offs, respectively. No such association became apparent in women.  
Conclusions: The present study revealed a U-shaped relation between IGF-I and all-cause 
mortality in male primary care patients.   
 




1. Introduction  
 
Insulin-like growth factor I (IGF-I), which is mostly carried by IGF binding protein 3 
(IGFBP-3), is generally accepted as a central mediator of endocrine and finally metabolic 
effects of the growth hormone (GH). Less than 1% are available as free bioactive IGF-I and in 
epidemiological studies usually the total IGF-I levels are used. Both disorders of the GH/IGF-
I axis, GH deficiency (GHD) characterized by low IGF-I serum values as well as acromegaly 
accompanied by GH and finally IGF-I oversecretion, are related to increased morbidity [1] 
and mortality [2]. Several studies demonstrated that GHD is associated with altered lipid 
profile, insulin resistance, and glucose intolerance due to an increase of visceral fat mass [3]. 
Therefore GHD showed a strong correlation with the metabolic syndrome which might be a 
reason for the observed higher mortality in GHD patients [4,5]. Moreover, an increased 
mortality has been reported also in acromegaly mostly due to cardiovascular disease (CVD) 
and respiratory diseases [1]. Therefore a U-shaped association between all-cause mortality 
and GH/IGF-I might be assumed.  
 
However, so far population-based studies investigating the relation of total IGF-I to mortality 
revealed conflicting results. The Rancho Bernardo Study [6] and the Framingham Heart Study 
[7] demonstrated inverse relations between IGF-I levels and ischemic heart disease mortality 
or all-cause mortality, respectively. A Danish study showed that high IGF-I levels were 
related to an increased all-cause mortality [8]. In contrast, two further population-based 
studies, the National Health and Nutrition Examination Survey (NHANES) [9] and the 
InChianti study [10] detected no association between IGF-I levels and mortality. The most 
likely reason for the conflicting results might be different sample sizes, definitions of outcome 
or confounders as well as different methods to measure IGF-I.  
 
Unfortunately the above-mentioned studies did not consider the possible U-shape of the 
association between IGF-I and mortality. In a recent analyses of the Study of Health in 
Pomerania (SHIP) [11], we investigated low as well as high IGF-I levels in relation to all-
cause mortality and demonstrated that low IGF-I levels were related to an almost two-fold 
higher mortality risk in men but not women. No associations were detected for high IGF-I 
levels. Possible reasons for the lack of an association between high IGF-I values and all-cause 
mortality might be the relative low number of events and the fact that a relatively healthy 
setting were reflected in such a population-based study design.  
 
In contrast to population-based studies, where much research on the association of IGF-I to 
mortality has been done, little is known about the potential effects of GH levels on mortality 
in primary care patients, which might be suffered more often from diseases. Therefore, the 
aim of the present study was to reinvestigate the association between low and high IGF-I 
levels and all-cause mortality in German primary care patients and comparing the obtained 
results with findings in the general German population [11].We hypothesize that even though 
this setting comprise more diseased subjects than the general population, low IGF-I and 
possible high IGF-I levels are associated with an increased all-cause mortality.  
 
2. Materials and methods  
 
2.1. Study design  
 
DETECT (Diabetes Cardiovascular Risk-Evaluation: Targets and Essential Data for 
Commitment of Treatment) is a large, multistage, and nationally representative study in 
Germany [12].On 16th and 18th September 2003 half a day, 3188 GPs completed a 
standardized assessment of the diagnostic and therapeutic profile of 55,518 unselected 
consecutive patients (59% women and 41% men; over 17 years). All patients completed a 
questionnaire on demographic data, complaints, illness history, knowledge about selected 
diseases and attitude towards those. The initial physicians' response rate was 60.2%, and 
further adjustments for nonresponse, regional distribution, and attrition were performed. In 
addition, a random subsample of 7519 patients participated in a more intensive standardized 
laboratory assessment. Of these patients, 6826 participated in a 1-year or 4-year follow-up, 
which was conducted in 2004 or 2007/2008, respectively. Another 279 subjects died during 
the follow-up period, and 693 subjects were lost to follow-up (Fig. 1). The last contact (last 
follow-up or day of death) was considered the end of that patient's follow-up. The comparison 
between subjects (n=693) who were lost to follow-up and the remaining patients (n=6826) 
revealed that the latter were, on average, 6 years older. However, no significant differences 
regarding the age- and sex-adjusted proportion of diabetes mellitus, ischaemic heart disease 
(IHD), liver, or renal diseases were found.  
 
Of the 6826 subjects, eleven subjects were excluded due to missing information on time of 
death. Furthermore, 663 patients with missing data for IGF-I and 86 patients with missing 
data for used continuous confounders were also excluded. Valid data were available in 2463 
men and 3603 women aged 18 to 95 years.  
 
2.2. Measurements  
 
For all patients, a comprehensive standardized clinical evaluation (patients' self-report and 
physicians' assessments) was performed. Information on diabetes mellitus, thyroid 
dysfunction, renal, liver, and ischemic heart disease (IHD) as well as height and weight were 
collected by physician-completed questionnaires. Body mass index [BMI=body weight 
(kg)/height [2] (m2)] was calculated. Smoking status and physical training were assessed by 
patients self-reports. Smoking was categorized into smokers and non-smokers. Patients who 
performed physical training for at least 2 h a week were classified as being physically active. 
Missing values in smoking status and physical activity were treated as separate group. To 
define acromegaly Schneider et al. [13] contacted 125 patients with IGF-I levels above the 
age- and sex-specific reference range. Of these 125 subjects, 7 patients had non-suppressed 
GH levels in an oral glucose tolerance test and were considered biochemically acromegalic.  
 
Blood samples were collected and shipped by courier at room temperature within 24 h to the 
central laboratory. Upon arrival in the central laboratory, the samples were centrifuged 
immediately, and the serum was stored at −20 °C until further processing. IGF-I was 
determined with an automated chemiluminescence system (Nichols Institute Diagnostics San 
Clemente, CA). The maximal intra- and interassay coefficients of variation were 5% and 7%, 
respectively. Reagents and secondary standards were used as recommended by the 
manufacturer. In every 5-years age-group, IGF-I levels were categorized into three groups 
(low, moderate, and high) according to the sex-specific 10th and 90th percentiles of the study 
population [11]. In the DETECT study, mortality and incident events were recorded by the 
respective primary care physician.  
 
2.3. Statistical analysis  
 
Categorical data were expressed as percentages; continuous data were expressed as mean 
(standard deviation). Univariate analysis was performed with χ2 test for categorical variables 
and Mann–Whitney- U-test for continuous distributions. In a first step, age-adjusted restricted 
cubic splines with 3 knots were used to detect a possible non-linear dependency of the log 
hazard function on serum IGF-I levels. Based on these results in a second step, multivariable 
Cox proportional hazard regression models with age as timescale were run to assess the 
associations between low as well as high IGF-I levels and all-cause mortality separately for 
men and women. The models were adjusted for BMI, smoking and physical activity. Further 
comorbidities including diabetes, thyroid, renal, liver diseases, and IHD were tested as 
potential confounders. Comorbidities which led to a N5% change in the estimate of interest 
remained in the models. Following this, in men the model was further adjusted for IHD and 
liver disease, whereas in women only liver disease was additionally included. The model 
assumption for the Cox proportional hazards regression model was checked with Schoenfeld 
residuals and log of the negative log of survival plots. Hazard ratios (HR) with 95% 
confidence intervals (CI) were calculated. A value of pb0.05 was considered statistically 
significant. Statistical analyses were performed with SAS 9.1 (SAS Institute Inc., Cary, NC, 
USA).  
 
3. Results  
 
3.1. General characteristics  
 
In the study population, 241 men and 353 women were classified as subjects with low IGF-I 
or high IGF-I levels, respectively. Comparisons regarding general characteristics are 
presented in Table 1. In both sexes, subjects with low IGF-I levels had higher BMI and were 
more often affected by diabetes mellitus or liver diseases. Additionally, men with low IGF-I 
levels were more often smokers and women with low IGF-I levels were less often physically 
active and less often affected by thyroid disease than subjects with moderate hormone levels. 
No differences were found between subjects with high and moderate IGF-I levels in both men 
and women.  
 
3.2. Association of IGF-I levels with mortality  
 
During 19,129 person-years of follow-up, 5.6% (n=137) of men and 2.9% (n=106) of women 
died. In a first step, we performed Cox regression with restricted cubic splines to assess the 
functional form of the association between IGF-I and mortality. The results showed a U-
shaped significant association in men but not women (Fig. 2). Results of univariate Kaplan–
Meier survival analysis and multivariate Cox proportional hazard analyses using IGF-I 
categorizations are presented in Fig. 3 and Table 2, respectively. In univariate Kaplan– Meier 
survival analysis, low and high IGF-I levels were associated with a higher all-cause mortality 
compared to moderate IGF-I levels in men (log-rank test: pb0.01). Analysis of IGF-I quartiles 
also revealed this U-shaped association (data not shown). Multivariable Cox proportional 
hazard analyses (Table 2) confirmed these results and showed that low and high IGF-I levels 
were independent predictors of all-cause mortality in men. In women, no relation between 
IGF-I levels and all-cause mortality were revealed. The exclusion of 11 patients with 
acromegaly, anterior pituitary insufficiency, or a pituitary adenoma did not affect these results 
[men: low IGF-I: hazard ratio (HR) 2.15 (95% confidence-interval (CI) 1.36–3.41), pb0.01; 
high IGFI: HR 2.24 (95%-CI 1.40–3.57), pb0.01; women: data not shown]. In further analysis 
we tested different definitions of low and high IGF-I levels by varying cut-offs (age specific 
15th–85th, 20th–80th, and 25th–75th percentiles). This analysis revealed increasing risks of 
all-cause mortality when lower IGF-I cut-offs were chosen to define low IGF-I and when 
higher IGF-I cut-offs to define high IGF-I in men (Fig. 4) but not women (data not shown). 
This finding confirmed the U-shaped association between IGF-I and mortality in men.  
 
4. Discussion  
 
The present study demonstrated a U-shaped association between IGF-I values and all-cause 
mortality considering data from a cohort of primary care patients in men but not women. Low 
and high IGF-I levels were related to a higher all-cause mortality compared to moderate IGF-I 
levels in men. The specificity of low IGF-I and high IGF-I levels increased with lower and 
higher cut-offs, respectively. These associations were not affected by acromegaly. For the first 
time, low as well as high IGF-I was identified as an independent risk factor for mortality in a 
single study population. In women, the number of cases and thus the power might be too low 
to detect an association between IGF-I and mortality. Further studies with higher number of 
cases in women are needed. Moreover, the follow-up time was between one and four years 
and the study might be a premature analysis for definitive determinants of mortality. 
Therefore, reverse causation (i.e. that low and high IGF-I levels are a consequence rather than 
a cause of factors contributing to increased mortality) cannot be ruled out with certainty. 
However we adjusted for or tested the effect of several diseases possibly associated with IGF-
I changes.  
 
Former studies showed that either low or high IGF-I levels were related to mortality. The 
findings regarding low IGF-I levels and all-cause mortality are in good agreement with a 
recent analysis from SHIP demonstrating an almost two-fold higher risk of all-cause mortality 
in men with low IGF-I levels [11]. In both studies SHIP and DETECT, the association 
between IGF-I and all-cause mortality was only detectable in men but not in women. While 
these findings are in good agreement with a previous analysis of DETECT showing already 
sex-specific differences regarding the association of IGF-I with dyslipidemia and IHD, the 
specific mechanisms underlying this sex-specifity remain to be investigated [14]. Beside 
SHIP, also the Framingham Heart Study confirmed our present results and found that with 
increasing levels of IGF-I all-cause mortality was reduced [7], unfortunately no sex-specific 
analyses were performed. On the other hand, the Rancho Bernardo Study [6] and the 
NHANES [9] found no association between IGF-I levels and all-cause mortality. However 
regarding cardiovascular mortality, the Rancho Bernardo Study detected that a 40 ng/ml 
decrease in IGF-I level was associated with a significant increase of 38% in risk of IHD 
mortality [6]. Unfortunately, the Rancho Bernardo Study also did not perform sex-specific 
analyses to clarify if sex differences were present. A recent Danish study, however, found the 
opposite of a positive association between high IGF-I levels and mortality [8].  
 
The observed association between low or high IGF-I serum concentration and mortality was 
not specific to a single aetiology. It is well established that acromegaly, a state accompanied 
by GH excess resulting in high IGF-I levels, and GHD characterized by low IGF-I serum 
values are associated with increased morbidity and mortality [2]. Therefore, the reported U-
shaped association between IGF-I and mortality is not unexpected in our study population. 
Outside the both extreme states of IGF-I regulation, acromegaly or GHD, the IGF-I axis is 
associated to many subclinical risk factors or phenotypes with increased mortality. Low IGF-I 
levels were detected in adults with anorexia, chronic obstructive pulmonary disease, liver 
cirrhosis, hypothyroidism, type 1 diabetes, and osteoporosis [15]. Former studies showed that 
critical illness is also associated with low IGF-I levels [15] suggesting that low IGF-I serum 
concentrations are rather a marker of pre-existing disease, than an independent risk factor of 
mortality. Therefore we carefully adjusted for medical morbidity and other clinical 
parameters, and continued to find an association between low as well as high IGF-I serum 
concentration and mortality in men. On the other side high IGF-I levels were related to 
cancer, renal disease, and hyperthyroidism [15]. Due to the broad range of function, IGF-I has 
nearly influence on all tissues of the human body. It is involved in cell proliferation, 
differentiation, as well as function. Regarding cardiovascular disease and cancer as main 
causes of mortality varies biological actions of IGF-I were found. For example experimental 
investigations demonstrated that IGF-I induces hypertrophy of cardiomyocytes and thus 
participates in the development of left ventricular hypertrophy (LVH) [16,17]. It has been 
demonstrated that cardiac IGF-I mRNA increased in parallel with hypertension and the onset 
of LVH [16]. Furthermore, IGF-I stimulates endothelial cells to release NO and therefore may 
represent a regulator of the vascular tone, which in turn interacts with LVH [18,19]. In terms 
of cancer, numerous patient studies revealed that high IGF-I levels were related to an 
increased risk of different cancer types. In cancer patients a higher expression of IGF-I and 
IGF-2 was found, which indicated that in addition to the mitogenic effect of IGFs on cancer 
cells, a possible role might exist for IGFs in tumor growth and progression [20]. However, 
population-based studies did not confirm the positive association between IGF-I and cancer. 
One possible molecular link between low IGF-I and mortality might be the interaction of the 
latter one and Forkhead box O (FOXO) transcription factors. These FOXO transcription 
factors induce cell growth arrest and apoptosis, which can be prevented by FOXO 
phosphorylation by the survival kinase AKT in response to growth factors like IGF-I [21]. In 
the absence of growth factors, FOXOs reside in the nucleus and up-regulate genes that inhibit 
the cell cycle, promote apoptosis and decrease oxidative stress [22]. Together, the IGF-I axis 
is complex and account for functional diversity and the exact mechanism by which IGF-I may 
cause an increased risk of death is currently not known, we propose IGF-I being a risk 
marker, rather than risk factor. A risk marker is not assumed to play an etiologic or direct 
causal role, but is mainly useful to improve our ability to predict risk. Therefore, further 
answers about causality and pathogenesis could be inferred from long-term observations 
which should be replicated in multiple cohorts.  
 
The aim of our study was to reanalyze the association between IGF-I and all-cause mortality 
in a collective of primary care patients and to compare results with findings of a population-
based study (SHIP). Both studies were conducted in the same country with the same health 
care system, and a broad range of confounding factors was considered. One point of strength 
of the present study was the measurement of IGF-I levels by same assay system. Limitations 
might have arisen from the single point determination of IGF-I which was measured only at 
baseline, assuming constant hormone levels in the study population. However, none of the 
above-mentioned population-based studies performed multiple measurements of IGF-I 
[6,7,9,10]. Furthermore, we did not measure IGF binding protein 3, the main binding protein, 
which might have an influence on the association between IGF-I and mortality. A further 
limitation was the high numbers of subjects with missing data for IGF-I levels in DETECT. 
However, comparison between patient with and without IGF-I measurements revealed no 
significant differences regarding sex, age, weight, height, proportion of diabetes mellitus, IHD 
thyroid, liver, and renal diseases.  
 
In conclusion, our analyses showed that men with low as well as high IGF-I levels have 
higher all-cause mortality in a cohort of primary care patients. These results suggest a U-
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